197 related articles for article (PubMed ID: 23432534)
1. Netazepide, a gastrin/CCK2 receptor antagonist, causes dose-dependent, persistent inhibition of the responses to pentagastrin in healthy subjects.
Boyce M; Warrington S; Black J
Br J Clin Pharmacol; 2013 Nov; 76(5):689-98. PubMed ID: 23432534
[TBL] [Abstract][Full Text] [Related]
2. Effect of repeated doses of netazepide, a gastrin receptor antagonist, omeprazole and placebo on 24 h gastric acidity and gastrin in healthy subjects.
Boyce M; Warrington S
Br J Clin Pharmacol; 2013 Nov; 76(5):680-8. PubMed ID: 23432415
[TBL] [Abstract][Full Text] [Related]
3. Effect of netazepide, a gastrin/CCK2 receptor antagonist, on gastric acid secretion and rabeprazole-induced hypergastrinaemia in healthy subjects.
Boyce M; Dowen S; Turnbull G; van den Berg F; Zhao CM; Chen D; Black J
Br J Clin Pharmacol; 2015 May; 79(5):744-55. PubMed ID: 25335860
[TBL] [Abstract][Full Text] [Related]
4. Single oral doses of netazepide (YF476), a gastrin receptor antagonist, cause dose-dependent, sustained increases in gastric pH compared with placebo and ranitidine in healthy subjects.
Boyce M; David O; Darwin K; Mitchell T; Johnston A; Warrington S
Aliment Pharmacol Ther; 2012 Jul; 36(2):181-9. PubMed ID: 22607579
[TBL] [Abstract][Full Text] [Related]
5. Randomised trial of the effect of a gastrin/CCK
Boyce M; van den Berg F; Mitchell T; Darwin K; Warrington S
Eur J Clin Pharmacol; 2017 Feb; 73(2):129-139. PubMed ID: 27796466
[TBL] [Abstract][Full Text] [Related]
6. Randomized Controlled Trial of the Gastrin/CCK
Abrams JA; Del Portillo A; Hills C; Compres G; Friedman RA; Cheng B; Poneros J; Lightdale CJ; De La Rue R; di Pietro M; Fitzgerald RC; Sepulveda A; Wang TC
Cancer Prev Res (Phila); 2021 Jun; 14(6):675-682. PubMed ID: 33782049
[TBL] [Abstract][Full Text] [Related]
7. Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.
Moore AR; Boyce M; Steele IA; Campbell F; Varro A; Pritchard DM
PLoS One; 2013; 8(10):e76462. PubMed ID: 24098507
[TBL] [Abstract][Full Text] [Related]
8. Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A.
Fossmark R; Sørdal Ø; Jianu CS; Qvigstad G; Nordrum IS; Boyce M; Waldum HL
Aliment Pharmacol Ther; 2012 Dec; 36(11-12):1067-75. PubMed ID: 23072686
[TBL] [Abstract][Full Text] [Related]
9. The gastrin receptor antagonist netazepide (YF476) prevents oxyntic mucosal inflammation induced by Helicobacter pylori infection in Mongolian gerbils.
Sørdal Ø; Waldum H; Nordrum IS; Boyce M; Bergh K; Munkvold B; Qvigstad G
Helicobacter; 2013 Dec; 18(6):397-405. PubMed ID: 23865485
[TBL] [Abstract][Full Text] [Related]
10. Netazepide Inhibits Expression of Pappalysin 2 in Type 1 Gastric Neuroendocrine Tumors.
Lloyd KA; Parsons BN; Burkitt MD; Moore AR; Papoutsopoulou S; Boyce M; Duckworth CA; Exarchou K; Howes N; Rainbow L; Fang Y; Oxvig C; Dodd S; Varro A; Hall N; Pritchard DM
Cell Mol Gastroenterol Hepatol; 2020; 10(1):113-132. PubMed ID: 32004755
[TBL] [Abstract][Full Text] [Related]
11. Skeletal effects of a gastrin receptor antagonist in H+/K+ATPase beta subunit KO mice.
Aasarød KM; Ramezanzadehkoldeh M; Shabestari M; Mosti MP; Stunes AK; Reseland JE; Beisvag V; Eriksen EF; Sandvik AK; Erben RG; Schüler C; Boyce M; Skallerud BH; Syversen U; Fossmark R
J Endocrinol; 2016 Aug; 230(2):251-62. PubMed ID: 27325243
[TBL] [Abstract][Full Text] [Related]
12. The gastrin-receptor antagonist L-365,260 inhibits stimulated acid secretion in humans.
Murphy MG; Sytnik B; Kovacs TO; Mertz H; Ewanik D; Shingo S; Lin JH; Gertz BJ; Walsh JH
Clin Pharmacol Ther; 1993 Nov; 54(5):533-9. PubMed ID: 8222496
[TBL] [Abstract][Full Text] [Related]
13. Potential clinical indications for a CCK
Boyce M; Lloyd KA; Pritchard DM
Curr Opin Pharmacol; 2016 Dec; 31():68-75. PubMed ID: 27710813
[TBL] [Abstract][Full Text] [Related]
14. YF476 is a new potent and selective gastrin/cholecystokinin-B receptor antagonist in vitro and in vivo.
Takinami Y; Yuki H; Nishida A; Akuzawa S; Uchida A; Takemoto Y; Ohta M; Satoh M; Semple G; Miyata K
Aliment Pharmacol Ther; 1997 Feb; 11(1):113-20. PubMed ID: 9042983
[TBL] [Abstract][Full Text] [Related]
15. Netazepide, a gastrin/cholecystokinin-2 receptor antagonist, can eradicate gastric neuroendocrine tumours in patients with autoimmune chronic atrophic gastritis.
Boyce M; Moore AR; Sagatun L; Parsons BN; Varro A; Campbell F; Fossmark R; Waldum HL; Pritchard DM
Br J Clin Pharmacol; 2017 Mar; 83(3):466-475. PubMed ID: 27704617
[TBL] [Abstract][Full Text] [Related]
16. Effects of YF476, a potent and selective gastrin/cholecystokinin-B receptor antagonist, on gastric acid secretion in beagle dogs with gastric fistula.
Takemoto Y; Yuki H; Nishida A; Ito H; Kobayashi-Uchida A; Takinami Y; Akuzawa S; Ohta M; Satoh M; Semple G; Miyata K
Arzneimittelforschung; 1998 Apr; 48(4):403-7. PubMed ID: 9608884
[TBL] [Abstract][Full Text] [Related]
17. The type 2 CCK/gastrin receptor antagonist YF476 acutely prevents NSAID-induced gastric ulceration while increasing iNOS expression.
Webb DL; Rudholm-Feldreich T; Gillberg L; Halim MA; Theodorsson E; Sanger GJ; Campbell CA; Boyce M; Näslund E; Hellström PM
Naunyn Schmiedebergs Arch Pharmacol; 2013 Jan; 386(1):41-9. PubMed ID: 23179899
[TBL] [Abstract][Full Text] [Related]
18. Effect of gastrin receptor antagonists on gastric acid secretion and gastrin and somatostatin release in the rat stomach.
Eissele R; Koop H; Bothe-Sandfort E; Arnold R
Digestion; 1992; 53(3-4):179-88. PubMed ID: 1363320
[TBL] [Abstract][Full Text] [Related]
19. (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N'-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist.
Semple G; Ryder H; Rooker DP; Batt AR; Kendrick DA; Szelke M; Ohta M; Satoh M; Nishida A; Akuzawa S; Miyata K
J Med Chem; 1997 Jan; 40(3):331-41. PubMed ID: 9022799
[TBL] [Abstract][Full Text] [Related]
20. JNJ-26070109 [(R)4-bromo-N-[1-(2,4-difluoro-phenyl)-ethyl]-2-(quinoxaline-5-sulfonylamino)-benzamide]: a novel, potent, and selective cholecystokinin 2 receptor antagonist with good oral bioavailability.
Morton MF; Barrett TD; Freedman J; Li L; Rizzolio MC; Prendergast CE; Wu X; Moreno V; Pyati J; Figueroa K; Cagnon L; Lagaud G; Ver Donck L; Ghoos E; Allison B; Rabinowitz MH; Shankley NP
J Pharmacol Exp Ther; 2011 Jul; 338(1):328-36. PubMed ID: 21493750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
